Aparna Gangopadhyay1, Subrata Saha2. 1. Department of Radiotherapy, Chittaranjan National Cancer Institute, 37 S.P. Mukherjee Road, Kolkata, India. 2. Department of Radiotherapy, Medical College Hospitals, Kolkata 88, College Street, Kolkata, India.
Abstract
OBJECTIVE: Pelvic side wall dose in locally advanced cervical carcinoma treated with definitive chemoradiation has been debated. The present study investigated relationship of disease recurrence with dose for the pelvic side wall. It also attempted to identify minimal dose that significantly reduced recurrence. METHODS: Pelvic side wall recurrence at median 24 months was assessed clinically and radiologically across three groups of patients receiving variable pelvic wall doses using no parametrial boost, external beam or interstitial boost, or dose escalated combined external beam with interstitial boost. RESULTS: At 24 months, recurrence occurred in 3/155 boost vs 40/130 no boost patients. (p < 0.0001). Receiver operating characteristic curve analysis demonstrated cut-off pelvic wall dose to be 58.9 Gy (p < 0.0001). Dose escalated combined boost showed no significant benefit compared to single modality parametrial boost (p = 0. 0.553). CONCLUSION: Mean pelvic wall dose of at least 58.9 Gy offers clinically significant benefit in pelvic wall control. Doses recommended by guidelines should be adhered to in the patients' best interests. ADVANCES IN KNOWLEDGE: This preliminary study determined a relationship between recurrence rates and dose to the pelvic side wall and also a cut-off dose that significantly improved pelvic wall control in locally advanced cervical cancer.
OBJECTIVE: Pelvic side wall dose in locally advanced cervical carcinoma treated with definitive chemoradiation has been debated. The present study investigated relationship of disease recurrence with dose for the pelvic side wall. It also attempted to identify minimal dose that significantly reduced recurrence. METHODS: Pelvic side wall recurrence at median 24 months was assessed clinically and radiologically across three groups of patients receiving variable pelvic wall doses using no parametrial boost, external beam or interstitial boost, or dose escalated combined external beam with interstitial boost. RESULTS: At 24 months, recurrence occurred in 3/155 boost vs 40/130 no boost patients. (p < 0.0001). Receiver operating characteristic curve analysis demonstrated cut-off pelvic wall dose to be 58.9 Gy (p < 0.0001). Dose escalated combined boost showed no significant benefit compared to single modality parametrial boost (p = 0. 0.553). CONCLUSION: Mean pelvic wall dose of at least 58.9 Gy offers clinically significant benefit in pelvic wall control. Doses recommended by guidelines should be adhered to in the patients' best interests. ADVANCES IN KNOWLEDGE: This preliminary study determined a relationship between recurrence rates and dose to the pelvic side wall and also a cut-off dose that significantly improved pelvic wall control in locally advanced cervical cancer.
Authors: Richard Pötter; Christine Haie-Meder; Erik Van Limbergen; Isabelle Barillot; Marisol De Brabandere; Johannes Dimopoulos; Isabelle Dumas; Beth Erickson; Stefan Lang; An Nulens; Peter Petrow; Jason Rownd; Christian Kirisits Journal: Radiother Oncol Date: 2006-01-05 Impact factor: 6.280
Authors: Akila N Viswanathan; Sushil Beriwal; Jennifer F De Los Santos; D Jeffrey Demanes; David Gaffney; Jorgen Hansen; Ellen Jones; Christian Kirisits; Bruce Thomadsen; Beth Erickson Journal: Brachytherapy Date: 2012 Jan-Feb Impact factor: 2.362
Authors: C A Perez; P W Grigsby; H M Camel; A E Galakatos; D Mutch; M A Lockett Journal: Int J Radiat Oncol Biol Phys Date: 1995-02-15 Impact factor: 7.038